JPMorgan: Earns More Than Ever And Its Capital Falls

JPMorgan remains rated a Buy as the bank shifts capital redeployment toward high-return businesses instead of expensive share repurchases. In the quarter, ROTCE was 23% (ex-extraordinary items) and tangible book value per share rose 10%, alongside robust capital allocation. Management expects higher regulatory capital requirements by 2028 and is deploying excess capital at 17%+ returns, supporting a favorable outlook for profitability.

Analysis

The market is likely to underappreciate that JPM is choosing compounding over cosmetic capital return. When a bank can reinvest incremental capital at a mid-teens return, buybacks become the lower-quality use of funds unless the stock is materially below intrinsic value; that should support book value per share and long-run ROE more than near-term EPS optics. The immediate loser is the subset of bank investors screening for headline repurchase yield, but that group is usually short-horizon money.

Second-order, this is a competitive widening event. JPM’s ability to fund growth while still staying ahead of future capital rules raises the bar for BAC, C, and GS/MS in businesses where scale and balance-sheet efficiency matter. Over 6-18 months, stronger capital deployment into high-return businesses should reinforce share gains in payments, cards, markets, and corporate banking, while less efficient competitors face a tougher choice between preserving distributions and funding growth.

The main risk is that the regulatory capital overhang becomes the dominant narrative before the compounding benefit is visible. If proposed capital requirements tighten faster than expected, JPM may be forced to maintain a larger buffer, delaying buybacks and pressuring near-term capital return math. Falsifiers would be a material drop in ROTCE toward the mid-teens, CET1 trending above management’s comfort zone without deployment, or a guidance cut tied to weaker loan growth / fee momentum.

Contrarian view: the consensus may be too focused on the lost buyback lever and not enough on the fact that repurchases at a full multiple are a weak use of capital for a bank with this return profile. If the stock sells off on lower buyback expectations, that may create a better entry rather than a thesis break. The key is whether incremental deployment keeps earning above cost of equity; if it does, the stock can compound even with a lower payout narrative.

Key Decisions for Investors

• Maintain/accumulate long JPM on any post-earnings pullback tied to buyback disappointment; 3-6 month horizon, thesis is intrinsic value compounding rather than capital return optics.
• Relative-value long JPM / short BAC or C for 3-12 months: JPM is better positioned to redeploy capital at higher incremental returns, while peers with weaker operating leverage are more dependent on buybacks to support EPS.
• For a cleaner sector expression, long JPM vs short KRE if the market starts pricing a broad bank-capital overhang; JPM should outperform regional banks on regulatory resilience and balance-sheet flexibility.
• Set a watch level on CET1 and ROTCE trends into the next quarter: if ROTCE stays above ~20% and tangible book grows mid/high-single digits, the bullish thesis is intact; if ROTCE slips into the mid-teens, reduce exposure.
• Avoid chasing short-dated calls; if using options, prefer 6-12 month structures after any selloff, since the catalyst path is gradual and tied to capital deployment cadence rather than one-quarter earnings surprise.